Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus - PubMed (original) (raw)

Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus

Stephen J Greene et al. Circulation. 2019.

No abstract available

Keywords: cardiovascular diseases; diabetes mellitus, type 2; guideline; heart failure; outcome assessment (health care); sodium-glucose transport proteins.

PubMed Disclaimer

Similar articles

• Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
  Testani JM, Inzucchi SE, Voors AA. Testani JM, et al. Circulation. 2019 May 21;139(21):2383-2385. doi: 10.1161/CIRCULATIONAHA.119.038854. Circulation. 2019. PMID: 31107618 No abstract available.
• Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
  Kondo H, Takahashi N. Kondo H, et al. Cardiovasc Res. 2019 May 1;115(6):e54-e57. doi: 10.1093/cvr/cvz073. Cardiovasc Res. 2019. PMID: 31077584 No abstract available.
• Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
  Katsiki N, Triposkiadis F. Katsiki N, et al. Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717. Curr Vasc Pharmacol. 2019. PMID: 30173648
• Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
  Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Giugliano D, et al. Cardiovasc Diabetol. 2021 Jan 11;20(1):17. doi: 10.1186/s12933-021-01213-w. Cardiovasc Diabetol. 2021. PMID: 33430860 Free PMC article. Review.
• Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.
  Bassi N, Fonarow GC. Bassi N, et al. Curr Cardiol Rep. 2018 Sep 26;20(11):112. doi: 10.1007/s11886-018-1050-3. Curr Cardiol Rep. 2018. PMID: 30259198 Review.

Cited by

• Time course of remnant cholesterol and the risk of heart failure.
  Liu X, Zhang Y, Tian X, Xu Q, Xia X, Chen S, Liu F, Wu S, Wang A. Liu X, et al. Endocrine. 2024 Sep 21. doi: 10.1007/s12020-024-04028-3. Online ahead of print. Endocrine. 2024. PMID: 39306642
• Diabetes and Heart Failure: A Literature Review, Reflection and Outlook.
  Li X, Zhou X, Gao L. Li X, et al. Biomedicines. 2024 Jul 15;12(7):1572. doi: 10.3390/biomedicines12071572. Biomedicines. 2024. PMID: 39062145 Free PMC article. Review.
• Preventing new-onset heart failure: Intervening at stage A.
  Upadhya B, Hegde S, Tannu M, Stacey RB, Kalogeropoulos A, Schocken DD. Upadhya B, et al. Am J Prev Cardiol. 2023 Oct 2;16:100609. doi: 10.1016/j.ajpc.2023.100609. eCollection 2023 Dec. Am J Prev Cardiol. 2023. PMID: 37876857 Free PMC article. Review.
• Two-Year Changes in Diabetic Kidney Disease Phenotype and the Risk of Heart Failure: A Nationwide Population-Based Study in Korea.
  Lee SE, Yoo J, Choi HS, Han K, Kim KA. Lee SE, et al. Diabetes Metab J. 2023 Jul;47(4):523-534. doi: 10.4093/dmj.2022.0096. Epub 2023 Apr 25. Diabetes Metab J. 2023. PMID: 37096376 Free PMC article.

References

1. 1. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S. Risk Factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633–644. doi: 10.1056/NEJMoa1800256 - DOI - PubMed
2. 1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi: 10.1161/CIR.0000000000000509 - DOI - PubMed
3. 1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720 - DOI - PubMed
4. 1. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. doi: 10.1056/NEJMoa1611925 - DOI - PubMed
5. 1. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Lower risk of heart failure and death in patients initiated on sodiumglucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249–259. doi: 10.1161/CIRCULATIONAHA.117.029190 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Medical

  • MedlinePlus Health Information